Evropska unija - italijanščina - EMA (European Medicines Agency)

stada arzneimittel ag - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - agenti antineoplastici - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. per ulteriori informazioni sullo stato del recettore del fattore di crescita epidermico umano 2 (her2), fare riferimento alla sezione 5. oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. per ulteriori informazioni sullo stato her2, fare riferimento alla sezione 5. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Evropska unija - italijanščina - EMA (European Medicines Agency)

biosimilar collaborations ireland limited - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - agenti antineoplastici - abevmy in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. abevmy in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. per ulteriori informazioni sullo stato del recettore del fattore di crescita epidermico umano 2 (her2), fare riferimento alla sezione 5. abevmy in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with abevmy in combination with capecitabine. per ulteriori informazioni sullo stato her2, fare riferimento alla sezione 5. abevmy, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. abevmy, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. abevmy in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. abevmy, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics [figo] stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. abevmy, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. abevmy in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. abevmy, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Evropska unija - italijanščina - EMA (European Medicines Agency)

merck sharp dohme ltd - papillomavirus umano di tipo 6 l1 proteine, tipo di papillomavirus umano 11 l1 proteine, papillomavirus umano di tipo 16 l1 proteine, tipo di papillomavirus umano 18 proteina l1 - papillomavirus infections; uterine cervical dysplasia; condylomata acuminata; immunization - vaccini - silgard è un vaccino per l'uso dall'età di 9 anni per la prevenzione di:lesioni genitali precancerose (cervicale, vulvare e vaginale), le lesioni anali precancerose cervicali tumori e cancri anali causalmente correlate ad alcuni oncogeni di papillomavirus umano (hpv) tipi di verruche genitali (condilomi acuminati) causalmente correlati a specifici tipi di hpv. vedi sezioni 4. 4 e 5. 1 per informazioni importanti sui dati che supportano questa indicazione. l'uso di silgard dovrebbe essere in conformità con le raccomandazioni ufficiali.

Švica - italijanščina - Swissmedic (Swiss Agency for Therapeutic Products)

eumedica pharmaceuticals ag - sulfamethoxazolum, trimethoprimum - compresse - sulfamethoxazolum 800 mg, trimethoprimum 160 mg, carboxymethylamylum natricum a, povidonum k 30, magnesii stearas, natrii docusas, pro compresso corresp. natrium 1.1 mg. - malattie infettive - synthetika

Švica - italijanščina - Swissmedic (Swiss Agency for Therapeutic Products)

haleon schweiz ag - diclofenacum natricum - emulgel - diclofenacum diethylaminum 23.2 mg corresp. diclofenacum natricum 20 mg, alcohol isopropylicus, propylenglycolum 50 mg, cocoylis caprylocapras, paraffinum liquidum, macrogoli aether cetostearylicus, carbomerum, diethylaminum, alcohol oleicus, aqua purificata, aromatica eukalyptusaroma cum limonenum geraniolum cumarinum eugenolum alcohol benzylicus citralum citronellolum e 321, e 321 0.2 mg, ad gelatum pro 1 g. - perkutanes antiphlogistikum - synthetika

Švica - italijanščina - Swissmedic (Swiss Agency for Therapeutic Products)

haleon schweiz ag - diclofenacum natricum - emulgel - diclofenacum diethylaminum 23.2 mg corresp. diclofenacum natricum 20 mg, alcohol isopropylicus, propylenglycolum 50 mg, cocoylis caprylocapras, paraffinum liquidum, macrogoli aether cetostearylicus, carbomerum, diethylaminum, alcohol oleicus, aqua purificata, aromatica eukalyptusaroma cum e 321 eukalyptusparfüm 0.2 mg limonenum geraniolum cumarinum eugenolum alcohol benzylicus citralum citronellolum e 321, ad gelatum pro 1 g. - perkutanes antiphlogistikum - synthetika

Švica - italijanščina - Swissmedic (Swiss Agency for Therapeutic Products)

merz pharma (schweiz) ag - ibuprofenum - compresse rivestite con film - ibuprofenum lysinum 684 mg corresp. ibuprofenum 400 mg, cellulosum microcristallinum, magnesii stearas, silica colloidalis anhydrica, Überzug: poly(alcohol vinylicus), macrogolum 3000, talcum, e 171, pro compresso obducto. - analgesico - synthetika

Švica - italijanščina - Swissmedic (Swiss Agency for Therapeutic Products)

axapharm ag - diclofenacum natricum - gel - diclofenacum diethylaminum 2.32 g corresp. diclofenacum natricum 2 g, propylenglycolum, aromatica, antiox.: e 321, excipiens ad gelatum pro 100 g. - perkutanes antiphlogistikum - synthetika

Evropska unija - italijanščina - EMA (European Medicines Agency)

merck sharp & dohme b.v. - vaccino contro il papillomavirus umano [tipi 6, 11, 16, 18, 31, 33, 45, 52, 58] (ricombinante, adsorbito) - condylomata acuminata; papillomavirus infections; immunization; uterine cervical dysplasia - papillomavirus vaccines - gardasil 9 è indicato per l'immunizzazione attiva di persone dall'età di 9 anni contro le seguenti malattie hpv:le lesioni precancerose e tumori che interessano la cervice, della vulva, della vagina e dell'ano provocata dal vaccino hpv typesgenital verruche condilomi acuminati) causate da specifici tipi di hpv. vedi sezioni 4. 4 e 5. 1 per informazioni su dati che supportano queste indicazioni. l'uso di gardasil 9 dovrebbe essere in conformità con le raccomandazioni ufficiali.

Švica - italijanščina - Swissmedic (Swiss Agency for Therapeutic Products)

axapharm ag - ibuprofenum - compresse rivestite con film - ibuprofenum 400 mg, ibuprofenum lysinum 684 mg, cellulosum microcristallinum, copovidonum, carboxymethylamylum natricum a magnesii stearas, Überzug: poly(alcohol vinylicus), talcum, macrogolum 4000, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, natrii hydrogenocarbonas, e 171, pro compresso obducto corresp. natrium 2.746 mg. - analgesico - synthetika